natgillin/translations-raw huggingface dataset:
This is a summary of the European public assessment report (EPAR) for Pioglitazone Actavis.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Pioglitazon Actavis.
Pioglitazone Actavis is used to treat type 2 diabetes in adults (aged 18 years or over), particularly those who are overweight.
Zdravilo Pioglitazon Actavis se uporablja za zdravljenje sladkorne bolezni tipa 2 pri odraslih (starejših od 18 let), zlasti tistih s prekomerno telesno maso.
The company that markets Pioglitazone Actavis will produce educational material for doctors prescribing the medicine, which will cover the possible risk of heart failure and bladder cancer with treatments that contain pioglitazone, the criteria for selecting patients and the need to review treatment regularly and stop treatment if patients are no longer benefiting.
Družba, ki trži zdravilo Pioglitazon Actavis, bo za zdravnike, ki bodo predpisovali zdravilo, pripravila izobraževalno gradivo, ki bo vključevalo možno tveganje za srčno popuščanje in rak sečnega mehurja pri zdravljenju s pioglitazonom, merila za izbiro bolnikov in potrebo po redni oceni zdravljenja ter njegovi prekinitvi, če to bolnikom ne koristi več.
Pioglitazone Actavis
Pioglitazon Actavis pioglitazon
The active substance in Pioglitazone Actavis, pioglitazone, makes cells (fat, muscle and liver) more sensitive to insulin, which means that the body makes better use of the insulin it produces.
Zdravilna učinkovina v zdravilu Pioglitazon Actavis, pioglitazon, poveča občutljivost celic (maščevja, mišic in jeter) za insulin, kar pomeni, da telo bolje izrablja insulin, ki ga proizvaja.
The Committee recommended that Pioglitazone Actavis be approved for use in the EU.
Priporočil je, da se zdravilo Pioglitazon Actavis odobri za uporabo v EU.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Pioglitazone Actavis has been shown to have comparable quality and to be bioequivalent to Actos.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Pioglitazon Actavis primerljivo raven kakovosti kot zdravilo Actos ter da mu je biološko enakovredno.
What measures are being taken to ensure the safe and effective use of Pioglitazone Actavis?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Pioglitazon Actavis?
This means that Pioglitazone Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Actos.
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Actos.
Because Pioglitazone Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je Pioglitazon Actavis generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
What are the benefits and risks of Pioglitazone Actavis?
Kakšne so koristi in tveganja, povezani z zdravilom Pioglitazon Actavis?
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Pioglitazone Actavis have also been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Pioglitazon Actavis upoštevati zdravstveni delavci in bolniki, so prav tako vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
For more information about treatment with Pioglitazone Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Pioglitazon Actavis preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Other information about Pioglitazone Actavis
Druge informacije o zdravilu Pioglitazon Actavis
Pioglitazone Actavis is a ‘generic medicine'.
Zdravilo Pioglitazon Actavis je „generično zdravilo“.
Because Pioglitazone Actavis is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine, Actos.
Ker je zdravilo Pioglitazon Actavis generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Actos.
For practical information about using Pioglitazone Actavis, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Pioglitazon Actavis naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
• in combination with metformin in patients who are not satisfactorily controlled on metformin alone, or with a sulphonylurea (another type of diabetes medicine) when metformin is not suitable in patients who are not satisfactorily controlled on a sulphonylurea alone;
• v kombinaciji z metforminom pri bolnikih, pri katerih zgolj z metforminom ni mogoče zadovoljivo uravnati bolezni, ali v kombinaciji s sulfonilsečnino (drugo vrsto zdravila za zdravljenje sladkorne bolezni), če metformin ni primeren, pri bolnikih, pri katerih sladkorna bolezen zgolj s sulfonilsečnino ni zadovoljivo uravnana;
What is Pioglitazone Actavis and what is it used for?
Kaj je zdravilo Pioglitazon Actavis in za kaj se uporablja?
Why is Pioglitazone Actavis approved?
Zakaj je bilo zdravilo Pioglitazon Actavis odobreno?
Pioglitazone Actavis contains the active substance pioglitazone.
Zdravilo Pioglitazon Actavis vsebuje zdravilno učinkovino pioglitazon.
It is not intended to provide practical advice on how to use Pioglitazone Actavis.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Pioglitazone Actavis can only be obtained with a prescription.
Predpisovanje in izdaja zdravila Pioglitazon Actavis je le na recept.
How has Pioglitazone Actavis been studied?
Kako je bilo zdravilo Pioglitazon Actavis raziskano?
How is Pioglitazone Actavis used?
Kako se zdravilo Pioglitazon Actavis uporablja?
How does Pioglitazone Actavis work?
Kako zdravilo Pioglitazon Actavis deluje?
Date of first authorisation: 13 March 2013 Date of latest renewal:
Datum prve odobritve: 13. marec 2013 Datum zadnjega podaljšanja:
Contains desiccant, do not eat.
Vsebuje sušilo, ne jejte.
Avoid taking alcohol until you have talked to your doctor.
Izogibajte se pitju alkohola, dokler se o tem ne pogovorite z zdravnikom.
- Calcium supplements and/or vitamin D supplements.
- dodatki kalcija in/ali dodatki vitamina D;
About 60% of the oral dose is eliminated within 48 hours.
Približno 60 % peroralnega odmerka se izloči v 48 urah.
You may notice this as dizziness when standing up.
Pojavi se vam lahko omotica, ko vstanete.
The event may be a chance finding or related to a mechanism currently not known (see section 5.1).
Dogodek je lahko naključen ali povezan s še neznanim mehanizmom (glejte poglavje 5.1).
A. LABELLING
A: OZNAČEVANJE
Renal clearance is about 250-300 ml/min.
Ledvični očistek je približno 250 do 300 ml/min.
- Second and third trimesters of pregnancy (see sections 4.4 and 4.6).
- Drugo in tretje trimesečje nosečnosti (glejte poglavji 4.4 in 4.6).
This applies especially to the medicines listed below taken at the same time with Actelsar HCT:
To velja zlasti za spodaj našteta zdravila, ki jih jemljete hkrati z zdravilom Actelsar HCT:
- Medicines to increase blood pressure, such as noradrenaline.
- zdravila za zvišanje krvnega tlaka, kot je noradrenalin;
Your doctor will normally advise you to stop taking Actelsar HCT before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Actelsar HCT.
Zdravnik vam bo praviloma svetoval, da zdravilo Actelsar HCT prenehate jemati, preden boste zanosili ali takoj, ko boste vedeli, da ste noseči, in vam svetoval, da namesto zdravila Actelsar HCT jemljete drugo zdravilo.
Actelsar HCT can have influence on the ability to drive and use machines.
Zdravilo Actelsar HCT lahko vpliva na sposobnost vožnje in upravljanja strojev.
*The event may have happened by chance or could be related to a mechanism currently not known.
*Morebiti gre za naključje ali pa je pojav povezan z mehanizmom, ki še ni znan.
The safety and efficacy of Actelsar HCT in children and adolescents aged below 18 have not been established.
Varnost in učinkovitost zdravila Actelsar HCT pri otrocih in mladostnikih, mlajših od 18 let, še nista bili dokazani.
See also information under the heading “Do not take Actelsar HCT”.
Glejte tudi informacije pod naslovom “Ne jemljite zdravila Actelsar HCT''.
- Amantadine (medicine used to treat Parkinson's disease and also used to treat or prevent certain illnesses caused by viruses).
- amantadin (zdravilo za zdravljenje Parkinsonove bolezni, s katerim zdravijo ali preprečujejo tudi nekatere bolezni, ki jih povzročajo virusi);
Do not use this medicine after the expiry date which is stated on the carton, blister or bottle label after “EXP”.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na škatli poleg oznake »EXP«.
Telmisartan is highly bound to plasma proteins (>99.5%) mainly albumin and alpha l-acid glycoprotein.
Telmisartan se obsežno veže na plazemske beljakovine (> 99,5 %), predvsem albumin in kisli glikoprotein alfa-1.
The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznamu EURD), opredeljenem v členu 107c(7)
Magnesium stearate (E470b) Potassium hydroxide Meglumine
Magnezijev stearat (E470b) Kalijev hidroksid
- Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
- Preobčutljivost na katero koli učinkovino ali katero koli pomožno snov, navedeno v poglavju 6.1.
With hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while the action persists for approximately 6-12 hours.
Hidroklorotiazid sproži diurezo v 2 urah, največji učinek doseže približno po 4 urah, njegovo delovanje pa traja približno 6 do 12 ur.
When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed.
Če je bil telmisartan uporabljen sočasno z digoksinom, so opažali mediano povečanje največje koncentracije digoksina (49 %) in njegove najmanjše koncentracije (20 %).
Very rare (may affect up to 1 in 10,000 people): Progressive scarring of lung tissue (interstitial lung disease)**
Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov): napredujoče brazgotinjenje pljučnega tkiva (intersticijska pljučna bolezen)**
Actelsar HCT with food and alcohol
Zdravilo Actelsar HCT skupaj s hrano in alkoholom
If your liver is not working properly, the usual dose should not exceed 40 mg/12.5 mg once a day.
Če vam jetra ne delujejo pravilno, običajni odmerek ne sme prekoračiti 40 mg/12,5 mg 1-krat dnevno.
Thrombocytopenia (sometimes with purpura)
trombocitopenija (včasih s purpuro)
What Actelsar HCT is and what it is used for
Kaj je zdravilo Actelsar HCT in za kaj ga uporabljamo
There are no adequate data from the use of Actelsar HCT in pregnant women.
Ni zadostnih podatkov o uporabi zdravila Actelsar HCT pri nosečnicah.
Furthermore, low blood pressure may be aggravated by alcohol, barbiturates, narcotics or antidepressants.
Poleg tega lahko nizek krvni tlak poslabšajo alkohol, barbiturati, narkotiki ali antidepresivi.
The overall incidence of adverse reactions reported with telmisartan (41.4%) was usually comparable to placebo (43.9%) in placebo controlled trials.
Skupna pogostnost neželenih učinkov, o kateri so poročali za telmisartan (41,4 %), je bila večinoma primerljiva s podatki za placebo (43,9 %) v kliničnih preskušanjih nadzorovanih s placebom.
It is important that you take Actelsar HCT every day until your doctor tells you otherwise.
Zdravilo Actelsar HCT morate jemati vsak dan, dokler vam ga bo zdravnik predpisoval.
Plasma concentrations of telmisartan are generally 2-3 times higher in females than in males.
Koncentracije telmisartana v plazmi so pri ženskah večinoma 2- do 3-krat večje kot pri moških.
- Hypersensitivity to other sulphonamide-derived substances (since hydrochlorothiazide is a sulphonamide-derived medicinal product).
- Preobčutljivost na druge sulfonamidne derivate (ker je hidroklorotiazid sulfonamidni derivat).
- Muscle relaxing medicines, such as tubocurarine.
- zdravila, ki sproščajo mišice, kot je tubokurarin;
The European Medicines Agency has waived the obligation to submit the results of studies with telmisartan hydrochlorothiazide in all subsets of the paediatric population in hypertension (see section 4.2 for information on paediatric use).
Evropska agencija za zdravila je odstopila od zahteve za predložitev rezultatov študij z zdravilom Actelsar HCT za vse podskupine pediatrične populacije s hipertenzijo (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
- Severe renal impairment (creatinine clearance <30 ml/min).
- Huda ledvična okvara (kreatininski očistek < 30 ml/min).
After a single dose of 14C-labelled telmisartan the glucuronide represents approximately 11% of the measured radioactivity in plasma.
Po enkratnem odmerku s C14 označenega telmisartana odpade na glukuronid približno 11 % radioaktivnosti, izmerjene v plazmi.
Pharmacotherapeutic group: Agents acting on the renin-angiotensin system; angiotensin II antagonists and diuretics, ATC code: C09DA07
Farmakoterapevtska skupina: zdravila z delovanjem na renin-angiotenzinski sistem; antagonisti angiotenzina II in diuretiki, oznaka ATC: C09DA07
Adverse reactions reported in all clinical trials and occurring more frequently (p≤0.05) with telmisartan plus hydrochlorothiazide than with placebo are shown below according to system organ class.
Neželeni učinki, o katerih so poročali v vseh kliničnih preskušanjih in so se pojavljali pogosteje (p ≤ 0,05) pri telmisartanu in hidroklorotiazidu kot pri placebu, so našteti po organskih sistemih.
Such conditions should be corrected before the administration of Actelsar HCT.
Tovrstna stanja je treba uravnati pred zdravljenjem z zdravilom Actelsar HCT.
If a re-administration of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun or to artificial UVA.
Če je treba diuretik ponovno uvesti, je priporočljivo izpostavljene dele telesa zaščititi pred soncem ali umetnimi ultravijoličnimi žarki.
Elimination Telmisartan: Following either intravenous or oral administration of 14C-labelled telmisartan most of the administered dose (>97%) was eliminated in faeces via biliary excretion.
Telmisartan: Po intravenskem ali peroralnem dajanju s 14C označenega telmisartana se je večina odmerka (> 97 %) izločila z blatom po biliarni poti.
The use of Actelsar HCT in children and adolescents up to the age of 18 years is not recommended.
Otroci in mladostniki Uporabe zdravila Actelsar HCT pri otrocih in mladostnikih do 18. leta ne priporočamo.
“Lot”, which is printed on the carton, refers to the batch number.
Oznaka »Lot« na škatli označuje številko serije.
Increase in dose of probenecid or sulfinpyrazone may be necessary.
Včasih je treba povečati odmerek probenecida ali sulfinpirazona.
Telmisartan may increase the hypotensive effect of other antihypertensive agents.
Drugi antihipertenzivi Telmisartan lahko poveča hipotenzivni učinek drugih antihipertenzivov.
Respiratory distress (including pneumonitis and pulmonary oedema)
dihalna stiska (vključno s pnevmonitisom in pljučnim edemom)
Some people feel dizzy or tired when taking Actelsar HCT.
Nekateri ljudje so med zdravljenjem z zdravilom Actelsar HCT omotični ali utrujeni.
Pharmacokinetic studies in patients with hepatic impairment showed an increase in absolute bioavailability up to nearly 100%.
Farmakokinetične raziskave so pri bolnikih z jetrno okvaro odkrile skoraj 100-odstotno povečanje absolutne biološke uporabnosti.
The terminal elimination half-life of hydrochlorothiazide is 10-15 hours.
Končna razpolovna doba izločanja je 10 do 15 ur.
You should also tell your doctor if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal.
Zdravnika prav tako obvestite, če se poveča občutljivost kože na sončne žarke in se znaki sončnih opeklin (rdečica, srbenje, oteklina, mehurji) pojavijo prej kot običajno.
If you accidentally take too many tablets you may experience symptoms such as low blood pressure and rapid heartbeat.
Če ste vzeli večji odmerek zdravila Actelsar HCT, kot bi smeli Če pomotoma vzamete preveč tablet, se lahko pojavijo simptomi, kot so nizek krvni tlak in pospešen srčni utrip.
Actelsar HCT is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.
Zdravila Actelsar HCT med nosečnostjo ne priporočajo; ne smete pa ga jemati, ko boste noseči več kot 3 mesece, ker lahko po tretjem mesecu nosečnosti resno škoduje vašemu otroku.
The effect of Actelsar HCT may be reduced when you take NSAIDs (non steroidal anti-inflammatory medicines, e.g. acetylsalicyl acid or ibuprofen).
Učinek zdravila Actelsar HCT se lahko zmanjša, če jemljete NSAR (nesteroidne antirevmatike, npr. acetilsalicilno kislino ali ibuprofen).
Food slightly reduces the bioavailability of telmisartan with a reduction in the area under the plasma concentration time curve (AUC) of about 6% with the 40 mg tablet and about 19% after a 160 mg dose.
Pri tem se območje pod krivuljo plazemske koncentracije v odvisnosti od časa (AUC) zmanjša za približno 6 % pri tabletah po 40 mg in za približno 19 % pri odmerkih po 160 mg.
You must tell your doctor if you think you are (or might become) pregnant.
Zdravniku morate povedati, če mislite, da ste (ali bi lahko bili) noseči.
An increase in cholesterol and triglyceride levels has been associated with thiazide diuretic therapy; however, at the 12.5 mg dose contained in Actelsar HCT, minimal or no effects were reported.
Z zdravljenjem s tiazidnimi diuretiki povezujejo povečanje ravni holesterola in trigliceridov, vendar za odmerek po 12,5 mg, ki ga vsebuje zdravilo Actelsar HCT, poročajo le o minimalnih ali nikakršnih tovrstnih učinkih.
In case of surgery or anaesthetics, you should tell your doctor that you are taking Actelsar HCT.
Če boste operirani ali boste dobili anestetike, morate zdravniku povedati, da jemljete zdravilo Actelsar HCT.
You should consult with your doctor if you need to adjust the dose of your other medicine while taking Actelsar HCT.
Z zdravnikom se morate posvetovati, ali je treba med jemanjem zdravila Actelsar HCT prilagoditi odmerek vašega drugega zdravila.
- Hyponatraemia and hypochloraemic alkalosis There is no evidence that Actelsar HCT would reduce or prevent diuretic-induced hyponatraemia.
- Hiponatriemija in hipokloremična alkaloza Ni podatkov, ki bi kazali, da zdravilo Actelsar HCT zmanjša ali prepreči hiponatriemijo, ki jo povzročajo diuretiki.
- Cholestyramine and colestipol, medicines for lowering blood fat levels.
- holestiramin in holestipol, zdravili za znižanje ravni maščob v krvi;
Angiotensin-II is a substance produced in your body which causes your blood vessels to narrow thus increasing your blood pressure.
Angiotenzin II je snov, ki nastaja v telesu in povzroča, da se krvne žile zožijo, kar zviša krvni tlak.
3 For further description, please see sub-section “Description of selected adverse reactions”.
3 Za podrobnejši opis glejte podpoglavje “Opis izbranih neželenih učinkov”.
Possible side effects of Actelsar HCT:
Možni neželeni učinki zdravila Actelsar HCT so:
Actelsar HCT is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
Uporaba zdravila Actelsar HCT ni priporočljiva v zgodnjem obdobju nosečnosti in ga ne smete jemati, če ste noseči več kot 3 mesece, ker lahko v tem obdobju resno škoduje vašemu otroku (glejte poglavje o nosečnosti).
Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
Med dejavniki tveganja za pojav akutnega glavkoma zaprtega zakotja so lahko alergije na sulfonamide ali penicilin v anamnezi.
If any of the above applies to you, tell your doctor or pharmacist before taking Actelsar HCT.
Če imate katero od naštetih stanj, povejte zdravniku ali farmacevtu preden boste vzeli zdravilo Actelsar HCT.
In addition, Actelsar HCT should be used with caution in patients with impaired hepatic function or progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic coma.
Zdravilo Actelsar HCT moramo previdno dajati tudi bolnikom z motnjami jetrnega delovanja ali napredujočo jetrno boleznijo, ker lahko že manjše spremembe ravnovesja tekočin in elektrolitov povzročijo jetrno komo.
Actelsar HCT is a combination of two active substances, telmisartan and hydrochlorothiazide in one tablet.
Zdravilo Actelsar HCT je kombinacija dveh zdravilnih učinkovin, telmisartana in hidroklorotiazida v eni tableti.
Take it as soon as you remember, then carry on as before.
Vzemite ga takoj, ko se spomnite, in z jemanjem nadaljujte kot običajno.
Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of telmisartan hydrochlorothiazide initiation.
Simptoma sta akutno poslabšanje ostrine vida ali očesna bolečina, ki se značilno pojavita v nekaj urah do nekaj tednih po začetku jemanja telmisartana/hidroklorotiazida.
Do not store above 30ºC
Shranjujte pri temperaturi do 30°C.
Al/Al blister, Al/PVC/PVDC blister and HDPE tablet container with LDPE cap and HDPE desiccant with silica filling.
Al/Al pretisni omot, Al/PVC/PVDC pretisni omot in HDPE vsebnik za tablete z LDPE pokrovčkom in HDPE sušilcem z silicijevim polnilom.
pentamidine, sparfloxacine, terfenadine, vincamine IV)
pentamidin, sparfloksacin, terfenadin, vinkamin i.v.)
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
Neželeni učinki so razvrščeni po pogostnosti, za katero veljajo naslednji kriteriji: zelo pogosti (≥ 1/10); pogosti (≥ 1/100 do < 1/10); občasni (≥ 1/1.000 do < 1/100); redki (≥ 1/10.000 do < 1/1.000); zelo redki (< 1/10.000), neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
Talk to your doctor before taking Actelsar HCT if you are suffering or have ever suffered from any of the following conditions or illnesses:
Pred začetkom jemanja zdravila Actelsar HCT obvestite zdravnika, če imate ali ste kadar koli imeli katero koli od naslednjih bolezenskih stanj ali bolezni:
Lupus-like syndrome, photosensitivity reactions, skin vasculitis, toxic epidermal necrolysis, erythema multiforme
lupusu podoben sindrom, fotosenzibilne reakcije, kožni vaskulitis, toksična epidermalna nekroliza, multiformni eritem
Experience with telmisartan/hydrochlorothiazide is modest in the patients with mild to moderate renal impairment, therefore periodic monitoring of potassium, creatinine and uric acid serum levels is recommended.
S kombinacijo telmisartan/hidroklorotiazid je malo izkušenj pri bolnikih z blago do zmerno zmanjšanim delovanjem ledvic, zato so priporočljivi periodični kontrolni pregledi serumskih ravni kalija, kreatinina in sečne kisline.
Hydrochlorothiazide is excreted almost entirely as unchanged substance in urine.
Hidroklorotiazidse skoraj v celoti izloči v obliki nespremenjene učinkovine s sečem.